Minimal Residual Disease Negativity Predicts Time to Next Treatment in Multiple Myeloma
Patients with sustained minimal residual disease negativity had longer time to next treatment, regardless of baseline risk characteristics
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.